Fakultni Nemocnice Ostrava

Ostrava, Czechia

13 recruiting

Showing 113 of 13 trials

Recruiting
Phase 3

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

Chronic Lymphocytic LeukemiaCLL
BeOne Medicines250 enrolled112 locationsNCT06846671
Recruiting
Phase 3

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Leukemia, Myeloid, Acute
Janssen Research & Development, LLC600 enrolled238 locationsNCT06852222
Recruiting
Phase 3

CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Novo Nordisk A/S1,280 enrolled285 locationsNCT07207811
Recruiting
Phase 2Phase 3

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Acute Myeloid LeukemiaMyelodysplastic SyndromesChronic Myelomonocytic Leukemia+1 more
Taiho Oncology, Inc.316 enrolled73 locationsNCT04256317
Recruiting
Phase 2

A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia

Small Lymphocytic LymphomaLeukemia, Lymphocytic, Chronic, B-Cell
Janssen Research & Development, LLC320 enrolled73 locationsNCT05963074
Recruiting
Phase 3

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

Multiple Myeloma
Janssen Research & Development, LLC795 enrolled242 locationsNCT06208150
Recruiting
Phase 3

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaLeukemia, B-cell+1 more
Loxo Oncology, Inc.662 enrolled144 locationsNCT05254743
Recruiting
Phase 3

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

Multiple Myeloma
Janssen Research & Development, LLC1,590 enrolled261 locationsNCT05552222
Recruiting
Phase 3

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

Ovarian Cancer
Daiichi Sankyo582 enrolled180 locationsNCT06819007
Recruiting
Phase 3

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

Multiple Myeloma
Kite, A Gilead Company450 enrolled122 locationsNCT06413498
Recruiting
Phase 3

Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

Leukemia
Daiichi Sankyo700 enrolled292 locationsNCT06578247
Recruiting
Phase 3

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Multiple Myeloma
European Myeloma Network B.V.1,594 enrolled210 locationsNCT05243797
Recruiting
Phase 3

A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant

Multiple Myeloma
European Myeloma Network B.V.1,000 enrolled33 locationsNCT06932562